Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)

Key Points

• Persistence of CAR T-cells at month 3 correlates with better clinical outcomes.
• The study found that higher T-cell persistence is linked to improved response rates.
• Assessment of T-cell persistence was crucial for evaluating the therapy's effectiveness.
• These findings support the need for monitoring T-cell levels post-treatment for optimal management.